CNTA Key Statistics, Chart & Performance
The current stock price of CNTA is 29.03 USD. In the past month the price increased by 19.32%. In the past year, price increased by 62.09%.
CNTA Latest News, Press Relases and Analysis
CNTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About CNTA
Company Profile
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 98 full-time employees. The company went IPO on 2021-05-28. The firm is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. The company also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Company Info
CENTESSA PHARMACEUTICALS-ADR
3rd Floor, 1 Ashley Road
Altrincham CHESHIRE GB
CEO: Saurabh Saha
Employees: 98
Phone: 447391789784
CENTESSA PHARMACEUTICALS-ADR / CNTA FAQ
Can you describe the business of CENTESSA PHARMACEUTICALS-ADR?
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 98 full-time employees. The company went IPO on 2021-05-28. The firm is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. The company also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Can you provide the latest stock price for CENTESSA PHARMACEUTICALS-ADR?
The current stock price of CNTA is 29.03 USD. The price increased by 0.17% in the last trading session.
What is the dividend status of CENTESSA PHARMACEUTICALS-ADR?
CNTA does not pay a dividend.
What is the ChartMill technical and fundamental rating of CNTA stock?
CNTA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for CNTA stock?
21 analysts have analysed CNTA and the average price target is 35.7 USD. This implies a price increase of 22.98% is expected in the next year compared to the current price of 29.03.
Can you provide the PE ratio for CNTA stock?
CENTESSA PHARMACEUTICALS-ADR (CNTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.57).
CNTA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CNTA. When comparing the yearly performance of all stocks, CNTA is one of the better performing stocks in the market, outperforming 95.05% of all stocks.
CNTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTA. The financial health of CNTA is average, but there are quite some concerns on its profitability.
CNTA Financial Highlights
Over the last trailing twelve months CNTA reported a non-GAAP Earnings per Share(EPS) of -1.57. The EPS decreased by -2.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.14% | ||
| ROE | -80.48% | ||
| Debt/Equity | 0.36 |
CNTA Forecast & Estimates
21 analysts have analysed CNTA and the average price target is 35.7 USD. This implies a price increase of 22.98% is expected in the next year compared to the current price of 29.03.